Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | HK1 | P19367 | 3/20 | 0.39 |
| ▸ | HK2 | P52789 | 3/20 | 0.39 |
| ▸ | AMDHD2 | Q9Y303 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CD69 | Q07108 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18849204 | 1.00 | MAPK1 (0.48) | MAPK1LMNAKDM4ECYP2D6CYP2C19 | |
| N-Acetylglucosamine SCHEMBL28987178 | 0.85 | MAPK1 (0.60) | MAPK1LMNAKDM4ECYP2D6CYP2C19 | |
| SCHEMBL18854303 | 0.85 | ALDH1A1 (0.42) | MAPK1ALDH1A1THRBCA1CA2 | |
| N-Acetylglucosamine SCHEMBL20798032 | 0.84 | MAPK1 (0.63) | MAPK1LMNAKDM4ECYP2D6CYP2C19 | |
| N-Acetylglucosamine SCHEMBL24105621 | 0.84 | MAPK1 (0.63) | MAPK1LMNAKDM4ECYP2D6CYP2C19 | |
| N-Acetylglucosamine SCHEMBL24978032 | 0.84 | MAPK1 (0.63) | MAPK1LMNAKDM4ECYP2D6CYP2C19 | |
| N-Acetylglucosamine SCHEMBL25229254 | 0.84 | MAPK1 (0.63) | MAPK1LMNAKDM4ECYP2D6CYP2C19 | |
| N-Acetylglucosamine SCHEMBL20842453 | 0.84 | MAPK1 (0.63) | MAPK1LMNAKDM4ECYP2D6CYP2C19 | |
| N-Acetylglucosamine SCHEMBL22748805 | 0.84 | MAPK1 (0.63) | MAPK1LMNAKDM4ECYP2D6CYP2C19 | |
| N-Acetylglucosamine SCHEMBL20621758 | 0.84 | MAPK1 (0.63) | MAPK1LMNAKDM4ECYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092400-A1 | Modified Oligonucleotides and Methods of Use | JANSSEN PHARMACEUTICA NV (BE) | 2025-03-20 | — | — | US | disclosed |
| US-12077757-B2 | Modified oligonucleotides and methods of use | JANSSEN PHARMACEUTICA NV (BE) | 2024-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12077757-B2 | Modified oligonucleotides and methods of use | NSUN2, ADAR, POLM | MAPK1 4642/4885LMNA 754/4885KDM4E 2847/4885 |
| US-20250092400-A1 | Modified Oligonucleotides and Methods of Use | NSUN2, ADAR, POLM | MAPK1 4662/4885LMNA 808/4885KDM4E 2928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.